INTRODUCTION
Macrophages (MFs) are innate immune cells present in each tissue, where they exert a wide range of functions. 1 Their versatility is exemplified by tumor-associated MFs (TAMs). TAMs can promote all phases of tumor development, from initiation to progression and metastasis. 2 One hallmark of TAMs is their enhanced production of the immunosuppressive cytokine interleukin 10 (IL-10).
3,4 IL-10 suppresses inflammation by inhibiting pro-inflammatory cytokine and chemokine (for example, IL-12, IL-1b, tumor necrosis factor-a (TNF-a) and interferon-g-induced protein 10) production as well as major histocompatibility complex class II and co-stimulatory receptor expression. 5 It is produced by immune cells in the tumor environment, especially TAMs, dendritic cells and regulatory T cells. In MFs, its production is triggered downstream of Toll-like receptor signaling, Fc receptor ligation, activation of receptor tyrosine kinases as well as interaction with apoptotic cells (ACs). 6, 7 A multitude of signaling pathways as well as post-transcriptional regulation are known to influence IL-10 expression, 7 whereas identification of fine-tuning mechanisms of IL-10 protein expression in complex environments such as in tumors is still required.
A major environmental component of tumors are dying cells, which program MFs to become immunosuppressive and presumably contribute to establishing the TAM phenotype. 8 One factor released by dying tumor cells is the sphingolipid sphingosine-1-phosphate (S1P).
9,10 S1P, upon binding to five specific G-protein-coupled receptors (S1PR1 --5), exerts powerful influence over major immune cell functions. 11 In MF biology, release of S1P from dying cancer cells accounts among others for IL-10 release through a so far unknown signaling mechanism. 10 Strikingly, S1P is involved in TAM generation by activating STAT3 (signal transducer and activator of transcription 3) downstream of S1PR1. 12, 13 A basic pattern of S1P receptor function is transactivation of receptor tyrosine kinases (RTKs), exemplified for S1PR4 and Her2/ neu (human epidermal growth factor receptor 2).
14 Reciprocal interaction was also observed, where RTK activation resulted in S1P formation and cross-activation of S1PRs. Among others, platelet-derived growth factor receptor and neurotrophic tyrosine kinase receptor A (TRKA/NTRK1), the nerve growth factor (NGF) receptor, cross-activated S1PR1/2. 15 Entwined signaling through S1P and RTKs might be of importance for MF function in cancer. Here we demonstrate that MF IL-10 secretion upon interaction with apoptotic breast cancer cells required autocrine NGF/TRKA signaling. TRKA was redistributed from the cytosol to the plasma membrane in a src-dependent manner downstream of S1PR activation. In accordance, TRKA signaling was also essential for IL-10 release by isolated TAM from murine PyMT breast cancer tissue.
RESULTS AC-induced IL-10 production by human MFs requires TRKA signaling MFs at tumor sites show an immunosuppressive phenotype, characterized among others by the release of IL-10, which might result from interaction with dying cells. 6, 10 Supernatants of apoptotic MCF-7 breast cancer cells (ACM), as compared with viable cell supernatant (VCM), were sufficient to induce IL-10 mRNA and protein secretion in human (Figures 1a and b) and murine MFs. 16 ACM from other solid tumor cell lines induced IL-10 mRNA and protein expression comparable to MCF-7 cells (Supplementary Figures S1a and b) . To elucidate the mechanisms of IL-10 induction in human MFs by dying cancer cells, we performed an adenoviral short-hairpin RNA (shRNA) screen, using the Galapagos SilenceSelect adenoviral shRNA collection (Leiden, The Netherlands). 17 Primary human monocytes were differentiated with macrophage colony-stimulating factor for 4 days, transduced with control adenovirus carrying an empty vector or target specific shRNAs for 24 h and further incubated for 5 days. Thereafter, MFs were treated for 24 h with ACM derived from MCF-7 cells at a cell --cell ratio of 1 MF to 5 ACs. Supernatant was collected and IL-10 protein content was analyzed using an electrochemiluminescence system. IL-10 levels did not differ between non-and empty vector-transduced cells. IL-10-specific shRNA reduced secreted IL-10 B75% compared with empty vector control (Figure 1c ). Of the targets whose depletion reduced IL-10 protein secretion, TRKA, unexpectedly, stood out regarding both the magnitude and reproducibility of IL-10 reduction (B60% compared with controls; Figure 1c ). TRKA-dependent IL-6 production was also observed in additional measurements of screening supernatants (data not shown), thus strengthening our interest in the chosen target.
To verify the involvement of TRKA in IL-10 regulation by ACs, we asked whether TRKA was activated by ACM. Human MFs were stimulated with ACM for 30 min, followed by TRKA immunoprecipitation and staining for its autophosphorylation (Y490). TRKA monomers and dimers were detected using a pan-TRKA antibody in the loading controls. Importantly, following immunoprecipitation, TRKA autophosphorylation was observed in ACM-treated MFs at a molecular weight corresponding to TRKA dimers, which was absent in unstimulated cells (Figure 1d) . Furthermore, K252a, a TRK family inhibitor, and GW441756, a putatively selective TRKA activity inhibitor, 18 markedly decreased ACMinduced IL-10 mRNA and protein (Figures 1e and f) .
IL-10 production downstream of TRKA requires PI3K and p38 MAPK Numerous signaling pathways contribute to IL-10 production. 7 We tested pharmacological inhibitors of major signaling pathways for their potential to repress ACM-induced IL-10. Expression of IL-10 often requires activation of STAT3, 7 a pathway activated downstream of S1PR1 in MFs. 12, 13 However, a nonselective janus kinase (JAK) inhibitor (JAK inhibitor I) as well as the STAT3 inhibitor STA-21 did not repress AC-induced IL-10 mRNA (Figure 2a ). For the mitogen-activated protein kinase (MAPK) family, only the p38 inhibitor SB203580 significantly reduced IL-10 mRNA induction by ACM, whereas extracellular signal-regulated kinase 1 and 2 (ERK1/2; UO126) and c-Jun N-terminal kinase (SP600125) inhibition was not effective (Figure 2b ). IL-10 production was furthermore strongly dependent on phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling, as the PI3K inhibitor Wortmannin as well as the mTOR inhibitor Rapamycin markedly decreased ACM-triggered IL-10 ( Figure 2c) . However, the most striking inhibition was observed when using PP2, an inhibitor of src family tyrosine kinases ( Figure 2c) .
Next, we asked whether the critical signaling pathways were interlinked and if their activation would require TRKA activity. Therefore, we assessed p38 and AKT phosphorylation in ACMstimulated MFs. AKT phosphorylation was rapidly induced by ACM and remained stable over 1 h (Figure 2d ). p38 MAPK phosphorylation in contrast increased over time (Figure 2e ). At 30 min, ACM-induced p38 phosphorylation was reduced to B50% with the TRK inhibitor K252a, but was not affected by either src tyrosine kinase or PI3K inhibitors (Figure 2f ). Contrarily, phosphorylation of AKT was drastically reduced (compared with Wortmannin) when src (PP2) or TRKA (K252a) were inhibited ( Figure 2g ). Thus, our data suggest an involvement of the PI3K/AKT pathway downstream of TRKA in IL-10 release from human MFs.
Signaling through TRKA requires its redistribution to the plasma membrane Generally, activation of TRKA is reported to depend either on the availability of its ligand NGF and/or transactivation by other RTKs without requiring NGF, but may also be regulated by the availability of TRKA itself. 19 The NGF monomer and the active dimer were both present in ACM in low quantities comparable to growth medium containing identical fetal calf serum (FCS) amounts. However, human MFs constitutively secreted high TRKA was immunoprecipitated from cell lysates, subjected to 6% SDS --PAGE and stained for phospho-TRKA (Y490). Additionally, TRKA was stained in the input controls, n ¼ 3. (e) IL-10 mRNA and ribosomal 18S RNA were quantified by qRT--PCR after 3 h of incubation with ACM and the inhibitors K252a and GW441756 (concentrations in mM). The ratio of IL-10 mRNA versus ribosomal 18S RNA in ACM treated cells was set to 1, nX6. (f ) ACM with or without inhibitors K252a (250 nM) and GW441756 (1 mM) was added to MFs and IL-10 protein was measured in supernatant after 24 h, nX5. Inhibitors were pre-incubated for 45 min before ACM treatment. (a --f ) All data are means ± s.e.m. *Pp0.05; **Pp0.01; ***Pp0.001.
Tumor cell death and macrophage activation S Ley et al levels of NGF indicated by the presence of the active dimer already 20 min after medium exchange and its accumulation over time. NGF release was not affected by the addition of ACM ( Figure 3a ) and intracellular levels were constant (Figure 3b ). In line, scavenging NGF using a neutralizing antibody inhibited ACMinduced IL-10 protein secretion after 24 h compared with the isotype control (Figure 3c ). Thus, although ACM-induced IL-10 release was dependent on the presence of NGF, the availability of NGF was not the decisive step. Transactivation of TRKA is frequently observed downstream of, for example, adrenergic receptor 2A, 20 adenosine receptors 19 or epidermal growth factor receptor and formyle peptide receptor. 21 As neutralizing NGF did not completely prevent ACM-induced IL-10 secretion, we suspected transactivation of TRKA to be involved. However, inhibition of potential transactivating receptors did not significantly interfere with ACM-mediated IL-10 production (Supplementary Figures S3a --c) .
Finally, we hypothesized that ACM might regulate TRKA availability in human MFs to increase IL-10. This hypothesis was strengthened by the observation that neither NGF nor other TRK family members induced IL-10 mRNA in MFs (Figure 3d ). Furthermore, NGF in contrast to ACM did not induce phosphorylation of p38 and AKT in MFs (Figure 3e ). PC-12 rat pheochromocytoma cells, which express high levels of TRKA at the plasma membrane, responded to both ACM and to a lesser extent to NGF with phosphorylation of AKT and p38 MAPK (Figure 3f ). This response was not triggered with other neurotrophins and was thus specific for NGF (Figure 3g ). These findings suggested that ACM increased the bioavailability of TRKA strongly in MFs and mildly in PC-12 cells. As ACM induced a rapid response, we did not expect expression regulation of TRKA.
TRKA activity in neurons is dependent on its localization. 22 When we investigated the localization of TRKA in primary human MFs before and after ACM stimulation, we detected remarkable differences. Control cells with pronounced CD36 þ (membrane marker) pseudopodia did not show TRKA at the plasma membrane, whereas strong TRKA accumulation at the plasma membrane was observed in ACM-stimulated MFs, accompanied by reduced pseudopodia (Figure 3h ). Shuttling of TRKA to the plasma membrane was also observed in ACM-stimulated HEK293 cells overexpressing hemagglutinin-tagged TRKA (Figure 3i ).
ACM activates S1PR to induce TRKA shuttling We previously observed that interfering with S1P release from dying tumor cells reduced IL-10 protein secretion by human MFs 10 by unknown mechanisms. Indeed, ACM from MCF-7 cells carrying a knockdown of sphingosine kinase 2 (SK2) (ACM-siSK2), which contains lower levels of S1P (ACM: 34.3 ± 9.9 pg/ml vs ACMsiSK2 17.7±4.21 pg/ml, determined as described in Weigert et al. 23 ), dampened IL-10 mRNA induction in MFs compared with ACM from control MCF-7 cells ( Figure 4a ). As human MFs express S1PR1 --4, 24 we used pharmacological inhibitors of these receptors to elucidate their relative involvement in IL-10 production. JTE-013, a S1PR2 (half-maximal inhibitory concentration 1.5 mM) as well as a S1PR4 inhibitor (half-maximal inhibitory concentration 4.5 mM), 25 reduced ACM-induced IL-10 production only when used at high concentrations (20 vs 1 mM), whereas the S1PR1/3 inhibitor VPC23019 did not (Figure 4b ). The observation that JTE-013 reduced IL-10 secretion only in high concentration suggested that more than one specific S1P receptor, or S1PR4 alone, was needed for ACM-triggered IL-10 secretion from MFs.
Next, we determined whether TRKA trafficking and/or activation were influenced by S1PR signaling in our system. JTE-013 blocked ACM-induced translocation of TRKA to the plasma membrane in MFs, which was unaltered when using the TRK inhibitor K252a or the NGF-neutralizing antibody (Figure 4c ). Additionally, JTE-013 markedly restored pseudopodia, which are retracted in an S1P-dependent manner. 26 Inhibition of src activity (PP2) also blocked TRKA translocation (Figure 4c ), which likely was the reason for decreased IL-10 release upon src inhibition (Figure 2c) . Furthermore, we observed that JTE-013 blocked AKT phosphorylation induced by ACM in primary MFs, which, as described above, was TRKA dependent (Figure 4d ). JTE-013 had no influence on p38 activation (Figure 4d) , which likely required a protein factor (Supplementary Figure S4) . Intriguingly, src phosphorylation was Graphs show quantification of ACM-mediated phospho-AKT and phospho-p38 protein expression, with unstimulated control set to 1, nX11. (f, g) Cells were stimulated for 30 min with ACM and inhibitors PP2 (10 mM), K252a (250 nM) and Wortmannin (100 nM). For quantification, ACM stimulation was set to 1, nX4. Inhibitors were pre-incubated for 45 min before ACM treatment. (a --g) All data are means ± s.e.m. *Pp0.05; **Pp0.01; ***Pp0.001.
Tumor cell death and macrophage activation S Ley et al markedly reduced by JTE-013, but not by K252a, again correlating to TRKA trafficking (Figure 4e ). These results indicate that src family kinase activation is required for TRKA shuttling to the plasma membrane. Interestingly, ACM induced a variety of well-known TAM marker mRNAs and targets of ACM-derived S1P signaling in MFs, 3, 4, 10, 13, 27 such as vascular endothelial growth factor (VEGF), adenosine receptor A2A (ADORA2A), indolamine 2,3--dioxygenase (IDO), IL-8, hypoxia inducible factor-1a (HIF-1a) and IL-1 receptor antagonist (IL-1ra), but had no effect on mRNA expression of mannose receptor 1 (MRC-1) (Figure 5a ). Secretion of tumorpromoting cytokines, such as IL-6, IL-8 and TNF-a, was drastically enhanced by ACM treatment (Figure 5c ), whereas pro-inflammatory, anti-tumoral IL-12p70 was not detectable. Compared with IL-10 regulation, no other marker under investigation showed exactly the same response to the used inhibitors, but inhibition of S1P and TRKA signaling reduced cytokine release (Figure 5d ). Of note, authentic S1P alone or in combination with VCM had no effect on cytokine production, arguing for a modulatory function of S1P in combination with other AC-derived factors ( Supplementary  Figures S5a and b) . In conclusion, S1P in ACM activates src downstream of S1PR, which is needed for TRKA translocation to the plasma membrane. Autocrine NGF then activates TRKA, which results in IL-10 induction mainly through PI3K/AKT/mTOR ( Figure 6 ).
TRKA signaling is needed for IL-10 release by murine TAMs We wondered whether TRKA signaling was active in primary tumor-infiltrating MFs. Therefore, we isolated CD11b þ myeloid cells from murine breast cancer tissue derived from PyMT transgenic mice and exposed them to pharmacological inhibitors that interfered with IL-10 production in ACM-stimulated human MFs. After 3 and 24 h, supernatants from CD11b þ cells, which were pre-dominantly CD11b high HLA-DR high F4/80 high MFs (Supplementary Figure S6) , were collected and cytokines were quantified. At both time points, the cells produced significant amounts of IL-10, IL-6, TNF-a and monocyte chemotactic protein-1 (MCP-1), whereas IL-12 or interferon-g were not released (Figures 7a and b) . However, the TRKA inhibitor K252a and SB203580 markedly suppressed IL-10 release from primary TAMs. In contrast, src inhibition was only effective at later time points, likely because of TRK being already present at the plasma membrane in isolated CD11b þ cells. IL-6 and TNF-a were regulated in a similar manner, being also dependent on TRKA. As K252a was already active when applied for 3 h and we did not detect signs of cell stress, we exclude cytotoxicity. Interfering with PI3K did not block cytokine production by CD11b þ cells (Figures 7c) , except for MCP-1, opposed to the human setup (Figure 2c) (Figure 8a) . The four distinct cell populations were seeded at identical densities (6000 cells per well) and 24 h later cytokines were again measured Tumor cell death and macrophage activation S Ley et al in supernatants. IL-12p70 and interferon-g were not detectable. IL-10 was measured in all four fractions, whereas only TAMs showed the previously observed regulation by inhibitors PP2 and K252a. IL-6 and TNF-a secretion was only pronounced in the TAM population and responded to the used inhibitors. When we seeded TAMs at higher density (20 000 cells per well) the observed effects were verified and MCP-1 was also detectable, with its release being dependent on src and TRKA (Figures 8b --e) . In conclusion, signaling pathways activated downstream of TRKA might be species specific. However, TRKA was involved in cytokine secretion from both human tumor cell-activated MFs and isolated murine TAMs that were primed by tumor cells in vivo.
DISCUSSION
In this study we describe a novel mechanism of tumor cellinduced IL-10 production by primary human MFs and verify the identified signaling components using CD45/CD11b þ cells as well as TAMs isolated from murine mammary carcinoma. Our data indicate a complex signaling network for IL-10 production, requiring S1PR/src-dependent trafficking of TRKA to the plasma membrane of primary human MFs, upon which autocrine NGF induces PI3K/AKT signaling.
We identified TRKA as an important regulator of IL-10 protein secretion induced by apoptotic cancer cells in a high-throughput adenoviral shRNA screen. TRKA and its ligand were previously associated with supporting or suppressing tumor growth, especially in breast cancer. 28, 29 Furthermore, TRKA modulates immune cell function. TRKA is highly expressed on monocytes, but downregulated upon differentiation to MFs. 30 Furthermore, we show that TRKA is not associated with the plasma membrane in naive MFs. Low TRKA expression in mature MFs compared with monocytes might enhance the sensitivity of TRKA activity regulation, as TRKA is especially prone to autoactivation when highly expressed. 31 Interestingly, lipopolysaccharide-stimulated human monocytes responded to neutralization of endogenous NGF with reduced IL-10 secretion. 32 Furthermore, NGF alone was sufficient to induce IL-10 in human monocyte-derived dendritic cells, 33 which we did not observe in human MFs. Thus, limited availability of TRKA might be macrophage specific.
Shuttling of TRKA to the plasma membrane of human MFs required S1PR signaling. We have shown that AC-secreted S1P rather shifts MFs to an anti-inflammatory phenotype ( Figure 5 ), 10 although the contribution of individual S1P receptors remained unknown. S1P receptors trigger diverse functional responses dependent on the relative expression profile and interaction with specific signaling modules. S1PR1, S1PR2 9 and, recently, S1PR3 34 were shown to be expressed by murine MFs, whereas S1PR1 --4 are expressed in the human counterparts. 24 S1PR4 is mainly expressed by immune cells 11 and might be the dominant S1P receptor on human MFs. 24 There are yet few functional studies concerning S1PR4 in immune cells. Interestingly, forced expression of S1PR4 in T cells inhibited proliferation accompanied by reduced secretion of IL-2 and interferon-g but enhanced IL-10 release. 35 Our findings that high concentrations of JTE-013 not and AKT to p38 and AKT content was followed by western blot (WB). For quantification, ACM treatment was set to 1, n ¼ 7. (e) MFs were treated with ACM with or without JTE-013, PP2 and K252a for 30 min (concentrations as in c) and relative expression of phosphorylated src and p38 content was followed by WB. The ratio of phospho-src to p38 was used for quantification. ACM treatment was set to 1 and statistics were performed using Student's t-test, n ¼ 5. (b--e) Inhibitors and neutralizing antibodies were pre-incubated for 45 min. All data are means ± s.e.m. **Pp0.01; *** ,### Pp0.001.
only reduced AC-dependent IL-10 production, but also prevented induction of candidate genes involved in pro-tumor MF function such as IL-6, IL-8, VEGF, ADORA2A, HIF-1a and IDO, some of which are usually associated with the hypoxic niche in tumors, 36 indicate a possible role of endogenous S1PR4 in modulating cytokine production by MFs. However, involvement of other S1PR cannot be excluded, as JTE-013 at concentrations being used here not exclusively affects S1PR4. S1PR1 --5 have been linked to activation of the PI3K/AKT pathway. This could partially explain the rapid AKT phosphoryla- Tumor cell death and macrophage activation S Ley et al tion in MFs after activation with ACM, which, judged by the localization data, was unrelated to TRKA activation and thus not related to IL-10 induction. However, AKT phosphorylation/ activation at 30 min, after TRKA shuttling occurred, was clearly dependent on S1PR, src and TRKA signaling, the same pathways that were critically involved in IL-10 induction by ACM. These findings strongly suggest that the autocrine NGF loop and the preceding S1PR-src-dependent translocation of TRKA was necessary for AKT phosphorylation. Opposed to AKT, p38 phosphorylation was only marginally reduced by the TRK inhibitor and independent of S1PR or src. Hereby, p38 might signal from activated TRKA in endosomes, whereas AKT activation preferably occurs at the plasma membrane, which is well described for AKT and ERK activation downstream of TRKA and other RTKs. 22, 37 Thus, for TRKA-mediated AKT activation, shuttling of TRKA to the plasma membrane in a src family kinase-dependent manner was needed. Src kinases are known as important mediators between G-proteincoupled receptors and RTKs, where they associate with the latter to influence functional responses. Src/TRKA interaction was shown to facilitate and enhance NGF signaling. 38 Our study adds a different facet to this important interaction by showing that TRKA shuttling also depends on src kinases. Interestingly, fibroblast growth factor receptor 1, another tyrosine kinase receptor, also requires src for endosomal activation, trafficking to the plasma membrane and signaling. 39 Future studies might identify the exact src family member(s) interacting with TRKA in human MFs.
In conclusion, the work provides evidence regarding the importance of NGF/TRKA signaling in cancer. Whereas an impact of this signaling axis on tumor cell survival in vitro is known, 28 its impact on the microenvironment was not defined. TAMs are of major importance, as they support tumor outgrowth in various ways, acting immunosuppressive and promoting angiogenesis. Thus, further studies are justified to dissect the impact of NGF on tumor-infiltrating immune cells. This might be of some value for cancer therapy, by providing a common target on both cancer cells and the tumor-supportive microenvironment.
MATERIALS AND METHODS
Cell culture and reagents MCF-7 breast carcinoma cells were maintained in RPMI-1640, HEK293 embryonic kidney cells and PC-12 rat pheochromocytoma cells in Dulbecco's modified Eagle's medium, each supplemented with 5 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heatinactivated FCS (PAA Laboratories, Cö lbe, Germany). Staurosporine, K252a, GW441756, SP600125, Wortmannin and Rapamycin were from SigmaAldrich (Steinheim, Germany); PP2, UO126 and STA-21 were from Enzo Life Sciences (Lö rrach, Germany); JTE-013 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); VPC23019 was from Avanti Polar Lipids (Alabaster, AL, USA); and JAK inhibitor 1 and SB203580 were from Merck (Darmstadt, Germany). Recombinant human b-NGF, BDNF, NT3, NT4 and macrophage Figure 6 . Scheme of IL-10 induction by ACM in MFs. S1P, generated by AC, induces src-dependent TRKA translocation to the plasma membrane, where autocrine NGF signals through PI3K/AKT and p38 to provoke IL-10 release. Besides S1P, at least one other factor, signaling through p38, is necessary for IL-10 induction. 
Generation of conditioned media
Generation of apoptotic cell supernatants (ACM) was performed as described before. 16 Cell death induction was routinely controlled (Supplementary Figure S2) . For generation of ACM lacking S1P, we used stable SK2-knockdown MCF-7 cells. 16 Cells were exposed to 0.5 mg/ml staurosporine for 1 h, washed twice with phosphate-buffered saline (PBS), followed by 6 h of incubation in full medium. Supernatants were harvested by filtration (0.2 mm; Roth, Karlsruhe, Germany).
Human monocyte isolation and culture Human MFs were generated from buffy coat monocytes (DRK-Blutspendedienst Baden-Wü rttemberg-Hessen, Institut fü r Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt, Germany). Peripheral blood mononuclear cells were isolated using Ficoll-Hypaque gradients (PAA Laboratories), washed twice with PBS and seeded in high-adherence culture dishes (Sarstedt, Nü mbrecht, Germany). Nonadherent cells were removed and the remaining monocytes were incubated for 7 days with RPMI-1640 containing 5% AB-positive human serum.
Adenoviral infection and IL-10 protein measurement CD14
þ cells were extracted using magnetic microbeads and the autoMACS separator (Miltenyi Biotec, Bergisch-Gladbach, Germany). Cells were resuspended in RPMI-1640 with 10% FCS, 5 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 100 ng/ml macrophage colonystimulating factor for 4 days in 384-well plates (Greiner Bio-One, Frickenhausen, Germany) at a density of 1 Â 10 4 cells per well. Transduction using Ad5C01-shRNA constructs and empty vector from Galapagos BV was performed at an IU of B85 for 24 h. Following target sequences were used: shTRKA: 5 0 -CGCTCTGGAGTCTCTCTCC-3 0 ; shIL-10: 5 0 -AGAGTGAA-GACTTTCTTTC-3 0 . After additional 5 days, transduced MFs were treated with ACM for 24 h. IL-10 protein in supernatants was measured by immunoassay using an electrochemiluminescence system (MA6000 Human IL-10 384 Tissue Culture Kit, SECTOR Imager 6000; Meso Scale Discovery, Gaithersburg, MD, USA).
Immunoprecipitation
Human MFs were lysed using NP40 Cell Lysis Buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na 3 VO 4 , 1% Nonidet P40 (NP40), 0.02% NaN 3 , 1mM PMSF, 1 Â Protease inhibitor mix and 1 Â PhosStop (Roche, Grenzach, Germany)). A total of 1 mg protein and 4 mg rabbit anti-TrkA (763; Santa Cruz Biotechnology) were incubated at 4 1C overnight with Dynabeads Protein G (Invitrogen, Darmstadt, Germany). Immunoprecipitation samples and crude cell lysates were subjected to 6% SDS --polyacrylamide gels and stained with rabbit anti-phospho-TRKA (Y490, 1:1000; Cell Signaling, Danvers, MA, USA) or rabbit anti-TrkA (763, 1:250; Santa Cruz Biotechnology).
RNA extraction and quantitative real-time PCR RNA from human MFs was extracted using pegGOLD RNAPure (Peqlab Biotechnologie, Erlangen, Germany). For reverse transcription of 1 mg mRNA, iScript cDNA Synthesis Kit (Bio-Rad, Munich, Germany) was used. Quantitative real-time PCR was performed with the MyiQ iCycler system (Bio-Rad) and Absolute QPCR SYBR Green Mix (ABgene, Hamburg, Germany). Relative mRNA expression was calculated with the Bio-Rad GeneEx gene expression macro, based on the ddCt method and normalized to 18S ribosomal RNA. The following primer pairs against human targets (Biomers, Ulm, Germany) were used: IL-10, 5 þ /CD11b þ immune cell populations were isolated from PyMT tumors and the relative amounts (%) of subpopulations within the CD45 þ /CD11b þ population are shown. (b--e) Cells were cultured at the indicated densities for 24 h with or without inhibitors PP2 (10 mM) and K252a (250 nM) and spontaneous cytokine secretion (IL-10, IL-6, TNF-a and MCP-1) was measured. MCP-1 was only detected at higher cell density, n ¼ 3. All data are means±s.e.m. Statistics were performed using Student' s t-test. *Pp0.05; **Pp0.01.
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, IL-6 and IL-8 primers were from Qiagen (Hilden, Germany).
Cytokine quantification
Human MF-derived cytokines were measured using CBA Human Inflammation Kits and cytokines from tumor-associated cells were measured using Mouse Inflammation Kits (BD Biosciences, Heidelberg, Germany) using a LSR Fortessa flow cytometer (BD Biosciences) and FCAP software (BD Biosciences).
Protein extraction and western blot analysis
Human MFs and PC-12 cells were starved overnight. Following treatments, cells were washed with ice-cold PBS and scraped into 400 ml lysis buffer (6.65 M urea, 10% glycerol, 1% SDS, 10 mM Tris, 1 Â Protease inhibitor mix, 1 Â PhosSTOP, 1 mM DTT, 7 mM Na 3 VO 4 , pH 7.4), sonicated and centrifuged (15 000 g, 30 min, 4 1C). Protein concentrations were determined using the Lowry method, equal amounts were subjected to 10% SDS --polyacrylamide gels and blotted on nitrocellulose membranes using a semidry transfer cell (Bio-Rad). Mouse anti-phospho-p38 (T180/Y182), rabbit anti-p38, rabbit anti-phospho-AKT (Ser473, D9E), rabbit anti-AKT and rabbit anti-phospho-src family (Tyr416) (all from Cell Signaling) were incubated on the membranes overnight at 4 1C. Secondary antibodies were IRDye 680 and 800 labeled (1:5000) and detected using the Li-COR Odyssey imaging system (Li-COR Biosciences, Bad Homburg, Germany). For detection of NGF, MFs were starved overnight, incubated for 20 min with control medium C (RPMI þ 2.5% FCS) or ACM. Resulting supernatants were concentrated using Vivaspin 4 PES membrane falcons (Satorius, Goettingen, Germany). Concentrates were subjected to 15% SDS --polyacrylamide gels. Anti-NGF (H-20, Santa Cruz Biotechnology) was used for NGF detection.
TRKA-hemagglutinin overexpression in HEK293
HEK293 cells were seeded on cover slips in six-well plates at a density of 5 Â 10 4 cells per well. After 24 h, cells were transfected with 3 mg hemagglutinin-tagged TRKA expression plasmid, 40 using JetPEI (Peqlab Biotechnologie). After 24 h, cells were starved overnight, stimulated with ACM or control medium for 30 min and subjected to immunoflourescence staining.
Immunoflourescence staining
MFs were harvested with trypsin, reseeded at a density of 1 Â 10 5 cells on a sterile cover slip (Menzel, Braunschweig, Germany) and cultured for 3 days. After overnight starvation, cells were stimulated, washed with PBS and fixed in 4% paraformaldehyde for 2 h at room temperature. Mouse anti-human-CD36 FITC (Immunotools) (1:100) in PBS was added for 2 h, followed by washing and permeabilization in 2% Triton X/PBS for 30 min. Cover slips were blocked for 1 h with 30% FCS/0.01% Triton X/PBS, followed by overnight incubation with rabbit anti-TrkA (763) (1:100) or, in the case of HEK293, with mouse anti-human HA.11 from Convance (Mü nster, Germany) (1:200) in 2% FCS/PBS at 4 1C. After washing with 0.01% Triton X/PBS, cells were incubated for 2 h with anti-mouse DyLight 594 (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and anti-rabbit Alexa Fluor 488 (1:100; Invitrogen) in 2% FCS/PBS. Cover slips were washed with 0.01% Triton X/PBS and mounted on microscope slides using Vectashield H-1400 mounting medium (Vector Labs, Burlingame, CA, USA). For image acquisition, the AxioVert 200 M fluorescence microscope equipped with the ApoTome and the Plan Apochromat 63 Â /1.40 Oil lens, RT, with a charge-coupled device camera and the AxioVision software was used (all from Carl Zeiss MikroImaging, Jena, Germany).
Isolation of cells from PyMT tumors
Mice carrying the PyMT oncogene under the control of the MMTV LTR promoter (FVB/N-TgN(MMTV-PyVT)634Mul/J) were a gift from Thomas Reinheckel (University of Freiburg, Freiburg, Germany). Tumor-bearing mice, 20 weeks old, were killed and the tumors extracted. A total of 1 g tumor tissue was minced with a scalpel and lysed in 2 ml Dulbecco's modified Eagle's medium, 3 mg/ml Collagenase 1A (Sigma-Aldrich) and 1 U/ml DNAse 1 (Promega, Mannheim, Germany) for 30 min at 37 1C. Lysis was stopped with Dulbecco's modified Eagle's medium þ 10% FCS and the lysate was further processed using Medicons (BD Biosciences) and the Medimachine (Keul, Steinfurt, Germany). After erythrocyte lysis, either CD11b-expressing cells were isolated via autoMACS or cell lysate was stained with CD45-Vioblue, CD11b-FITC, HLR-DR-APC (Miltenyi Biotec), F4/80 --PE-Cy7 (eBioscience Frankfurt, Germany), Ly6G-PE and Ly6C-PerCPCy5. 5 
